ROSWELL PARK CANCER INSTITUTE announced the formation of Global Biotechnology & Cancer Therapeutics, a for-profit company that will support biotech and life-sciences startups. “GBCT will allow outside biotechnology companies to partner with a scientifically respected entity that will provide infrastructure for drug development and investment — everything from clinical trials to anticancer agents and vaccines,...
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
